News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MacroGenics, Inc. (MGNX) To Present Pre-Clinical Data On Novel DART Candidate MGD010 For Autoimmune Disorders At IMMUNOLOGY 2014


4/28/2014 5:19:02 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will present pre-clinical data on its novel DART® candidate for the treatment of autoimmune disorders, MGD010, at IMMUNOLOGY 2014, the American Association of Immunologists Annual Meeting, in Pittsburgh, PA. The poster, titled "Development of human B-lymphocyte targeted bi-specific DART® molecules for the treatment of autoimmune disorders," will be presented Monday, May 5, 2014, from 2:30-3:45 pm ET in Hall A, poster THER5P.830, abstract number 200.9.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES